Latham & Watkins Advises GoodCell in US$17.9 Million Preferred Equity Round

GoodCell (LifeVault Bio), the company decoding human health to extend and improve the quality of life through technology powered by science, has announced that it has raised US$17.9 million in a preferred equity financing round. GoodCell intends to use this latest funding to continue the development of its technology for detecting and monitoring accumulated genetic variation within blood cells. The financing will also help advance the company’s big data analytics platform to validate novel applications for its health tracking and risk identification solutions through GoodCell Diagnostics and its personal biobanking service.

Latham & Watkins LLP represented GoodCell in the transaction with a Boston-based corporate deal team led by partner John Chory and associates Spencer Ricks and Belinda King.